• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Doug Kass
    • Bruce Kamich
    • Jim Cramer
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing

CVS Is Aggressive and Optimistic, and I'm Long the Shares

The firm's Q3 earnings easily beat Wall Street's expectations.
By STEPHEN GUILFOYLE
Nov 06, 2020 | 10:18 AM EST
Stocks quotes in this article: CVS

CVS Health (CVS) reported the firm's fiscal third quarter performance on Friday (this) morning. The firm posted adjusted EPS of $1.66, easily beating Wall Street's expectations. As for revenue generation, CVS put a $67.1 billion print to the tape. That's good enough for 3.5% year over year growth, and good enough to beat the street by more than half a billion dollars. The firm also increased it's outlook for full year profitability going into the final three months. Let's dig in.

Breakdown

Pharmacy Services, the largest business unit of the firm's three, contributed $35.7 billion in revenue, down 0.85% year over year, but above consensus of $35.1 billion, as price compression and some client losses did take a toll. Retail Sales increased 5.9% to $22.7 billion, easily beating the $22.3 billion that the industry was looking for. Lastly, Healthcare Benefits posted sales of $18.7 billion, growth of 8.8%, and also above consensus as operations that had formerly been part of Aetna were combined with what was already in place.

On the quarter, CEO Larry Merlo stated, "Our strong third quarter results demonstrate continued execution of our long-term strategic plan that is transforming the way healthcare is delivered." He's not kidding. The firm offers everything from health insurance to front of the store, over the counter retailing, to flu shots to broad Covid-19 testing. The caveat? Larry Merlo will not be around long-term himself. Merlo will retire in February, stepping aside for current Aetna President Karen Lynch to take over the management of the entire business. Merlo, who held the post of chief executive since 2011, will remain on the Board at least until the annual meeting in May.

Looking Forward

CVS is nothing if not both aggressive and optimistic. Looking ahead, the firm now expects to see adjusted full year EPS land in a range spanning $7.35 to $7.45, up from prior guidance of $7.14 to $7.27. The firm also increased expected cash flow from operations significantly from $11 billion - $11.5 billion to $12.75 billion - $13.25 billion.

This is despite the firm having added 76K full and part-time employees since March, bringing headcount up to about 300K. CVS Health as recently as October indicated that the firm would need to add another 15K to payroll in the pharmacy as the firm prepares for a tough Covid and Flu season.

On that note, CVS now runs more than 4K Covid testing sites that have administered more than 6 million tests. Of these sites, the firm plans to have roughly 1K ready for rapid testing by year's end.

The Chart

Perhaps the most interesting item visible on this chart is the downward sloping Pitchfork that begins in early June. CVS broke out of that formation in October, and in early November strength ahead of earnings, has now retaken both the stock's 50 day and 200 day SMAs. Notice the increase in November trading volume over October's as well.

Clearly, in my opinion, there has been recent professional accumulation. Maybe it was in anticipation of earnings. Maybe the spread of the pandemic. Perhaps this is either a vote against Merlo's leadership or to the contrary a vote in favor of Lynch.

I am long the shares, and I have added on weakness. Why? Because the shares - again, my opinion - are still cheap at just eight times earnings. Oh, and they do pay investors, even at these prices, 3.26% just to hang around. My target price is $73. Retaking last year's multi year high of roughly $77 is certainly not out of the question.

(CVS Health is a holding in Jim Cramer's Action Alerts PLUS member club. Want to be alerted before Jim Cramer buys or sells CVS? Learn more now.)

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

At the time of publication, Stephen Guilfoyle was Long CVS equity.

TAGS: Dividends | Earnings | Investing | Stocks | Technical Analysis | Trading | Health Care Equipment & Services | Healthcare

More from Investing

Bearish Bets: 2 Nasdaq Stocks You Should Consider Shorting This Week

Bob Lang
Apr 18, 2021 10:30 AM EDT

These names are displaying both quantitative and technical deterioration.

Navigating the Cycles of the Market

James "Rev Shark" DePorre
Apr 17, 2021 10:00 AM EDT

How Recency Bias and the Pareto Principle impact your trading decisions.

Netflix Reports Earnings on Tuesday: 5 Important Things to Watch

Eric Jhonsa
Apr 17, 2021 8:00 AM EDT

Along with its total subscriber adds, keep an eye on Netflix's regional growth rates, as well as its free cash flow guidance and content spending outlook.

Market Indices Continue to Hide Crazy Rotational Action

James "Rev Shark" DePorre
Apr 16, 2021 4:41 PM EDT

Fundamentals and valuations are secondary to shifting money into certain sectors.

Is the Market Wrong on Bank of America? Here's What the Charts Say

Bruce Kamich
Apr 16, 2021 2:21 PM EDT

Let's check in again on BAC after its latest earnings.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 08:05 AM EDT JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    How recency bias and the Pareto Principle impact y...
  • 02:42 PM EDT PAUL PRICE

    Wednesday on Real Money Pro

    Make this stock a 'part' of your portfolio.
  • 04:44 PM EDT PAUL PRICE

    Pretty Incredible + Hard to Believe

  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2021 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login